What The LEO Foundation does

The LEO Foundation is a Danish enterprise foundation established in 1984 to secure the long-term continuation and development of LEO Pharma A/S, a global pharmaceutical company specializing in medical dermatology that was itself founded in 1908. It operates as a permanent, ownerless controlling shareholder with no personal beneficiaries, and discharges its purpose through three interconnected activities: (1) engaged ownership of approximately 80% of LEO Pharma (held via wholly-owned LEO Holding A/S, with Nordic Capital as the remaining minority shareholder); (2) philanthropic grant-making, deploying open-competition Research Grants (three annual funding rounds) to independent dermatology research worldwide, with cumulative grants of approximately DKK 1.8 billion since inception; and (3) responsible management of a financial asset portfolio of approximately DKK 18.8 billion (roughly EUR 2.5 billion) spanning liquid assets (listed shares, government and covered bonds, credit) and alternatives (structured credit, private equity, infrastructure, real estate), held through LEO Holding A/S. Its internal technology stack is administrative rather than product-oriented: there is no proprietary technology platform, AI/ML capability, or commercial software product; instead the Foundation runs a structured grant application and scientific evaluation process supported by an international panel of independent experts.

The Foundation serves two distinct constituencies. Its philanthropic beneficiaries are academic researchers and research institutions worldwide working on the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases, reached through the open-competition Research Grants program. Its other constituency is indirect: through its controlling stake in LEO Pharma, it underwrites the development and global distribution of medical dermatology therapies for patients with skin diseases. Revenue is not disclosed at the Foundation level; the Foundation's inflows are investment returns on its DKK 18.8 billion portfolio together with the value created at LEO Pharma, while its outflows are philanthropic grants and the cost of a small Copenhagen-based team of fewer than 20 employees led by CEO Peter Haahr, CSO Anne-Marie Engel, and CIO Morten Stampe Christensen. The Foundation's head office is at Lautrupsgade 7, Copenhagen Ø, Denmark.

Name

The LEO Foundation

Legal name

LEO Foundation

Website

https://leo-foundation.org

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1–10 employees

Short description

The LEO Foundation is a Danish enterprise foundation that permanently owns approximately 80% of LEO Pharma A/S, the global medical dermatology pharmaceutical company, while also serving as one of the world's largest private funders of independent skin research and managing a DKK 18.8 billion investment portfolio. It has no owners or personal beneficiaries and serves academic researchers worldwide through open-competition grants and, indirectly, patients via LEO Pharma.

Ownership category

akta.pro rank

Product category

Philanthropic Foundation

NAICS

Grantmaking Foundations (813211), Religious, Grantmaking, Civic, Professional, and Similar Organizations (813)

SIC

Investors, Nec (6799)

akta.pro primary industry

Private Foundations (BPAGAKAA)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Dermatology research grants
• Pharmaceutical ownership
• Enterprise foundation
• Skin disease research
• Philanthropic grant-making

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales

Revenue model

1. Philanthropic Grant-Making: The Foundation provides grants to dermatology and skin disease research. The Foundation does not generate revenue from this activity; rather, it deploys its financial resources to support scientific research.
2. Engaged Ownership of LEO Pharma: The Foundation holds approximately 80% controlling ownership of LEO Pharma A/S, a global pharmaceutical company specializing in medical dermatology. This ownership generates value through the company's operations and strategic development.
3. Investment Returns: The Foundation's investment portfolio generates returns to support LEO Pharma's long-term continuation and strategic development, as well as providing a growing basis for philanthropic grants. Financial assets of approximately DKK 18.8 billion (~EUR 2.5 billion) are invested across liquid assets (listed shares, government bonds, covered bonds, credit) and alternative investments (structured credit, private equity, infrastructure, real estate).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

The LEO Foundation is a Danish enterprise foundation that operates through three interconnected activities: (1) engaged ownership of LEO Pharma A/S as an approximately 80% controlling shareholder, supporting the global pharmaceutical company's development in medical dermatology; (2) philanthropic Research Grants provided through an open-competition process with three annual funding rounds to support independent skin disease research worldwide; and (3) management of a diversified financial investment portfolio of approximately DKK 18.8 billion through its wholly-owned subsidiary LEO Holding A/S.

Product overview

The LEO Foundation operates as a Danish enterprise foundation with three interconnected activities: (1) engaged ownership of LEO Pharma A/S, holding approximately 80% controlling shareholder position in the global pharmaceutical company specializing in medical dermatology; (2) provision of philanthropic Research Grants through an open competition process with three annual funding rounds to support dermatology research worldwide; and (3) management of financial assets of approximately DKK 18.8 billion through its wholly owned subsidiary LEO Holding A/S, which includes liquid assets and alternative investments to generate returns supporting LEO Pharma's development and the Foundation's grant-making activities.

Differentiator

Problem solved

Functional benefit

Products and services

• LEO Pharma Ownership Engaged ownership stake of approximately 80% controlling share in LEO Pharma A/S, a global pharmaceutical company and leader in medical dermatology founded in 1908, setting standards of care for people with skin conditions.
• Research Grants Open competition research grants given to support the best dermatology research projects worldwide, with three annual funding rounds evaluating applications for underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases.
• Financial Investments Investment management through wholly-owned subsidiary LEO Holding A/S, managing approximately DKK 18.8 billion in financial assets across liquid assets (listed shares, government bonds, covered bonds, credit) and alternative investments (structured credit, private equity, infrastructure, real estate).

Quantifiable outcome

• DKK 59 million granted for inflammatory skin disease research
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Carlsberg Foundation: Danish enterprise foundation that is the largest shareholder in Carlsberg and a major scientific research funder. Closely analogous enterprise foundation model combining controlling industrial ownership with substantial scientific grantmaking in Denmark.
• Lundbeck Foundation: Danish enterprise foundation controlling H. Lundbeck and one of Denmark's largest research grantmakers, with a focus on neuroscience. Highly comparable to LEO Foundation in Danish enterprise foundation structure, controlling pharma ownership, and grantmaking within a specific therapeutic area.
• Novo Nordisk Foundation: Danish enterprise foundation that is the controlling shareholder of Novo Nordisk and one of the world's largest private funders of scientific research. Closely comparable to LEO Foundation in structure: Danish enterprise foundation with controlling pharma ownership combined with major scientific grantmaking.
• Velux Foundations: Danish philanthropic foundations focused on research, sustainability, and social causes. Comparable as Danish research-focused grantmaking foundations with strong scientific orientation and operating in overlapping Danish philanthropic ecosystems with LEO Foundation.
• Robert Wood Johnson Foundation: US-based philanthropic foundation focused on health and healthcare. Comparable as a large health-focused foundation with substantial grantmaking activities, though operating in a different national jurisdiction.
• Howard Hughes Medical Institute: US-based medical research organization that is one of the largest private funders of biomedical research globally, supporting scientists across many institutions. Comparable as a major private biomedical research foundation with significant grant deployment.
• Wellcome Trust: UK-based independent charitable foundation that is one of the world's largest funders of biomedical and health research. Comparable as a major privately-endowed research foundation with substantial grant deployment into biomedical science globally.
• A.P. Møller Foundation: Danish enterprise foundation that is the controlling shareholder of A.P. Møller-Mærsk and a major supporter of Danish scientific, educational, and humanitarian initiatives. Directly comparable as a Danish enterprise foundation with controlling industrial ownership and significant philanthropic activities.

Broad incumbents

• Bill & Melinda Gates Foundation: The world's largest private philanthropic foundation with massive global health and biomedical grantmaking programs. Comparable as a major health-focused research grantmaking foundation, though at much greater scale and broader scope than LEO Foundation.

Emerging players

• Kavli Foundation: US-based foundation funding basic scientific research across multiple disciplines including neuroscience and physics. Comparable as a science-focused grantmaking foundation, though with broader scientific scope and US-centric operations rather than dermatology specialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/leo-foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The LEO Foundation